• Labiana strengthens its human health division with the launch of a new business line that offers an analytical service for marketers of cannabis flowers for therapeutic purposes.
• The company has completed the validation that allows it to certify that batches comply with the specifications required by current regulations.

Madrid, November 27, 2024 – Labiana, the pharmaceutical laboratory specialized in animal and human health and listed on BME Growth, has completed the validation of the analytical methods for cannabis flowers intended for therapeutic use according to the European Pharmacopoeia. This allows the company to certify producers or distributors worldwide that their batches comply with the specifications required by current regulations.

In this way, Labiana strengthens its human health division with the launch of a new business line that offers an analytical service for GMP producers or marketers of cannabis flowers for therapeutic purposes in the countries where regulations allow their distribution and commercialization.

This is a prerequisite that leads to the corresponding certificate of analysis issued by the Technical Management department, which confirms that the product complies with the regulations described in the European Pharmacopoeia required for its commercialization. Only then can the product be made available to the market, patients, or other laboratories for therapeutic purposes.

Demonstrated experience

Labiana already has the first real application of this service. Specifically, it is working on the stability study of cannabis flowers and on the analytical validation for microbiological count for the Spanish company Trichome Pharma, in which Labiana holds a stake and which has a license for the cultivation of medicinal cannabis for R&D purposes granted by the Spanish Agency for Medicines and Health Products (AEMPS).

Likewise, the group continues to advance in the validation of analytical methods for terpenes, other compounds of the plant that are relevant in the field of research due to their properties and potential effects in the modulation and synergies with cannabinoids.

This milestone for Labiana coincides with the recent approval by the Council of Ministers of Royal Decree 903/2025, of October 7, which regulates the therapeutic use of cannabis in hospitals for certain conditions for which other drugs have proven ineffective. Although its introduction is still incipient, the decree sets the conditions for preparing and using magistral formulas with medicinal value from cannabis under medical supervision.

According to Francisco Fernández Campos, Director of Research and Development at Labiana and associate professor at Pompeu Fabra University, “the validation of analytical methods for cannabis flowers for therapeutic purposes opens an important business path for Labiana, considering advances in research and also in regulation, following the approval of Royal Decree 903/2025, which now regulates the therapeutic use of cannabis in hospitals.”